Even using Australian raw materials won’t mean total safety. I...

First 81 Last

Share
Profile

Follow
SMXtimes50folds

4,885 Posts.

557

31/08/20

22:16

Post #: 46969971
Share

Originally posted by meghotcop: ↑

Good point. SAMR would be most unlikely for production in Australia. Also, the production in China would use Australian produce, the result being "made in China" from 100% imported Australian ingredients. My guess. I am not sure how the Chinese consumer views it.

It would be a little harder to sell it as a premium product (compared to before), sale price concessions can be assumed thus leading to more pressure on the margins.

I could not find the exact amount needed for the investment in China, but the CR of about $38 mio is more than half their annual turnover or 10% of total shares issued.

All this would be absolutely no problem, if BUB could demonstrate they can make profit. We can post here until the goats (just joking) come home, it will always come back to one issue: PROFIT. Even a little, in a quarter, and then so on. ... But, we have to wait (for Godot), or become LTholders, or ...

For rational investor, the long term holding strategy is not that appealing, because any company with persistent quarterly losses is a company on borrowed time (WHA is a case in point).

On the other hand, I have great admiration for Kirsty Carr. She absolutely drives BUB. She (she started the goat milk business with her sister) and her enthusiasm enticed me to invest in the first place. Probably the best sales woman around.

The whole financial situation, however, is somewhat vexing and disappointing..

Expand

Even using Australian raw materials won’t mean total safety. I wouldn’t trust any of the Chinese management when it comes to something so delicate as baby food.

BUB made a huge mistake I am afraid by producing the product in China......

BUB Price at posting: 91.5¢ Sentiment: None Disclosure: Not Held
4 Upvote

1 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

First 81 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 17.0¢		Change -0.010(5.56%)		Mkt cap ! $156.2M

Open	High	Low	Value	Volume
18.0¢	18.0¢	17.0¢	$93.74K	530.0K

Buyers (Bids)

No.	Vol.	Price($)
23	779512	17.0¢

Sellers (Offers)

Price($)	Vol.	No.
17.5¢	361176	15

View Market Depth

No.	Vol.	Price($)
23	779512	0.170
14	695081	0.165
17	421543	0.160
23	1338222	0.155
23	1528488	0.150

Price($)	Vol.	No.
0.175	361176	15
0.180	705316	24
0.185	1124255	12
0.190	342378	12
0.195	322491	6

Last trade - 12.04pm 27/06/2025 (20 minute delay)

BUB (ASX) Chart

Even using Australian raw materials won’t mean total safety. I...

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Even using Australian raw materials won’t mean total safety. I...

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News